Congratulations to Dr. Eduardo Candelario-Jalil’s lab on their recent publication in Experimental Neurology

We are thrilled to announce the publication of a groundbreaking study from Dr. Eduardo Candelario-Jalil’s lab titled “Pharmacological Inhibition of Receptor-Interacting Protein Kinase 2 (RIPK2) Elicits Neuroprotective Effects Following Experimental Ischemic Stroke.”

This remarkable research sheds new light on potential therapeutic avenues for ischemic stroke, one of the leading causes of disability and mortality worldwide. Dr. Candelario-Jalil and his team’s findings offer promising insights into the neuroprotective effects of pharmacological inhibition of RIPK2, providing hope for improved treatment strategies and better outcomes for stroke patients.

Join us in celebrating Dr. Eduardo Candelario-Jalil and his team for their invaluable contribution to neuroscience and stroke research! Their dedication, innovation, and passion for advancing science are truly commendable, and we are grateful for the impact their work will have on improving lives. To read the full article click the link below.